Evolus, Inc.
EOLSDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
EOLS Earnings Report
EPS Est: $-0.09 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How EOLS's past catalysts played out
Botulinum toxin, Type A
Glabellar Frown Lines
PrabotulinumtoxinA-Xvfs
Glabellar Frown Lines
Botulinum purified neurotoxin, Type A
Glabellar Frown Lines
DWP-450 (Botulinum purified neurotoxin, Type A)
Glabellar Frown Lines
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Botulinum toxin, Type A | Phase 3 | Glabellar Frown Lines | - | - |
PrabotulinumtoxinA-Xvfs | Phase 2 | Glabellar Frown Lines | - | - |
Botulinum purified neurotoxin, Type A | Phase 2 | Glabellar Frown Lines | - | - |
DWP-450 (Botulinum purified neurotoxin, Type A) | Phase 2 | Glabellar Frown Lines | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Evolus, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Evolus, Inc.'s (EOLS) pipeline across Phase 3, Phase 2. Its lead program is Botulinum toxin, Type A (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Evolus, Inc.'s next FDA catalyst?→
Evolus, Inc.'s (EOLS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EOLS biotech catalysts?→
Add EOLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Evolus, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.